NASDAQ$SANA
Sana Biotechnology Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Sana's clinical programs progressed, leadership team enhanced, and strategic repositioning increased focus on immunologic diseases.
Sana Biotechnology reported its Q3 2024 financial results, highlighting advancements in its hypoimmune technology across three clinical programs and five indications. The company increased its focus on type 1 diabetes and B-cell mediated autoimmune diseases, appointed a new Chief Scientific Officer, and anticipates data readouts in 2024 and 2025. Sana's cash position is $199.0 million, expected to fund operations into 2026.
- Advanced hypoimmune technology in three trials across five indications.
- Enrolling patients in trials for type 1 diabetes, B-cell mediated autoimmune diseases, and oncology.
- Increased focus on type 1 diabetes and B-cell mediated autoimmune diseases to accelerate development and prolong capital runway.
- Cash position of $199.0 million with expected cash runway into 2026.
Headline financials
Revenue & EPS history
Sana · Revenue · Quarterly
$0
Forward guidance
Sana Biotechnology anticipates sharing data in 2024 and 2025 across multiple clinical settings, including type 1 diabetes, B-cell mediated autoimmune diseases, and oncology.
Tailwinds
- Initial data from UP421 trial in Type 1 Diabetes expected in 2024 and/or 2025.
- Initial data from GLEAM trial in B-cell mediated autoimmune diseases expected in 2024 and/or 2025.
- Data from VIVID trial in Oncology expected in 2025.
- Strategic repositioning to increase focus on immunologic diseases.
- Cash runway into 2026.
Headwinds
- Payments related to ongoing activities combined with the strategic repositioning may increase the 2024 operating cash burn above prior guidance of less than $200 million.
- The value of success payment liabilities fluctuate significantly with changes in Sana’s market capitalization and stock price.
- Uncertainties in clinical trials.
- Economic, market, and social disruptions.
- Risks inherent in drug development.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-1.2%
Avg return
Earnings day
-2.0%
Avg return
5 days after
+4.1%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+22.3%
Q2 2022
Best reaction
-25.3%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.5% | -15.3% | -18.6% | |
| Q3 2025 | -0.2% | +3.9% | +25.7% | |
| Q2 2025 | +7.3% | +14.0% | +16.4% | |
| Q1 2025 | +0.6% | -1.7% | +56.9% | |
| Q4 2024 | -17.7% | -16.6% | -40.4% | |
| Q3 2024 | -6.8% | -14.2% | -25.8% | |
| Q1 2024 | -25.3% | -21.2% | -30.5% | |
| Q4 2023 | +5.6% | -8.1% | -6.3% | |
| Q3 2023 | -14.8% | -10.3% | -4.1% | |
| Q2 2023 | -3.8% | -1.3% | -4.5% | |
| Q1 2023 | +7.2% | +11.8% | +8.9% | |
| Q4 2022 | +2.3% | +2.3% | +51.8% | |
| Q3 2022 | -14.1% | -21.6% | -22.2% | |
| Q2 2022 | +22.3% | +18.3% | -3.0% | |
| Q1 2022 | -5.6% | -11.9% | -11.4% | |
| Q4 2021 | +21.1% | +19.5% | +45.6% | |
| Q3 2021 | -5.7% | -3.3% | -19.2% | |
| Q2 2020 | +10.2% | +9.5% | +40.5% | |
| Q2 2021 | +10.2% | +9.5% | +40.5% | |
| Q1 2021 | -13.1% | -1.9% | +9.9% | |
| Q4 2020 | -5.7% | -4.1% | -23.7% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro